Breaking News Instant updates and real-time market news.

ABT

Abbott

$40.58

-0.2059 (-0.50%)

, ALR

Alere

$42.61

-0.55 (-1.27%)

15:25
10/17/16
10/17
15:25
10/17/16
15:25

Abbott, Alere preparing for trial, CTFN says

Even as Abbott (ABT) and Alere (ALR) continue to work with a court ordered mediator over their disagreements regarding their merger agreement, the two companies are preparing for a trial, says CTFN. Reference Link

ABT

Abbott

$40.58

-0.2059 (-0.50%)

ALR

Alere

$42.61

-0.55 (-1.27%)

  • 19

    Oct

  • 06

    Nov

ABT Abbott
$40.58

-0.2059 (-0.50%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
ALR Alere
$42.61

-0.55 (-1.27%)

08/09/16
08/09/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 2. Chevron (CVX) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company offers "impressive financial resilience and dividend sustainability." 2. Alere (ALR) upgraded to Buy from Neutral at BTIG with analyst Dane Leone saying the 10-K helped to alleviate concerns that material deficiencies exist with the current financial model and is more comfortable with forecasts, and with the $56 price stated within the Abbott (ABT) merger agreement. 3. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Credit Suisse with analyst Jason West saying the presence of activist investor Marcato could provide a "floor" for the stock and a be a win-win for shareholders. 4. Waste Management (WM) upgraded to Overweight from Sector Weight at KeyBanc with analyst Joe Box saying he believes volumes are undergoing a positive inflection point and that the company's price gains are sustainable. 5. Skyworks (SWKS) upgraded to Outperform from Underperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/16
PIPR
08/24/16
NO CHANGE
PIPR
Abbott, Alere likely to agree to reduced takeover price, says Piper Jaffray
Piper Jaffray analyst Alex Olvera believes that Abbott (ABT) is building evidence to bolster its case that Alere (ALR) has undergone a material adverse change since Abbott agreed to acquire it. However, the analyst says he thinks that Delaware, where any litigation between the companies would occur, has never ruled that a material adverse change has occurred in any other case. Consequently, Olvera says there is "a high probability" that the takeover price for Alere will be lowered by 10%-15%. There is a "medium probability" that the cash component of the offer will be reduced and replaced with stock or Contingent Value Rights, according to the analyst. Finally, there is a "low probability" of the merger being terminated, he wrote.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.

TODAY'S FREE FLY STORIES

NCSM

NCS Multistage

21:17
04/27/17
04/27
21:17
04/27/17
21:17
Syndicate
NCS Multistage 9.5M share IPO priced at $17.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CLDR

Cloudera

21:14
04/27/17
04/27
21:14
04/27/17
21:14
Syndicate
Cloudera 15M share IPO priced at $15.00, above the range »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

21:05
04/27/17
04/27
21:05
04/27/17
21:05
General news
Japan's data dump revealed tepid inflation and mixed growth figures »

Japan's data dump…

AOS

A.O. Smith

$54.42

1.45 (2.74%)

20:16
04/27/17
04/27
20:16
04/27/17
20:16
Downgrade
A.O. Smith rating change at KeyBanc »

A.O. Smith downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

FB

Facebook

$147.70

1.14 (0.78%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Hot Stocks
Facebook improves 'Rights Manager' content protection system »

Facebook introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 08

    May

  • 16

    May

AAWW

Atlas Air

$59.80

0.4 (0.67%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Downgrade
Atlas Air rating change at Stifel »

Atlas Air downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

UTHR

United Therapeutics

$120.50

0.51 (0.43%)

20:00
04/27/17
04/27
20:00
04/27/17
20:00
Hot Stocks
United Therapeutics announces $250M repurchase program »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

CYTR

CytRx

$0.68

-0.121 (-15.02%)

19:56
04/27/17
04/27
19:56
04/27/17
19:56
Hot Stocks
CytRx: Former 'SPA' for aldoxorubicin no longer applicable »

CytRx disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

EEX

Emerald Expositions Events

19:52
04/27/17
04/27
19:52
04/27/17
19:52
Syndicate
Emerald Expositions Events 15.5M share IPO priced at $17.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

GOOG

Alphabet

$874.25

2.52 (0.29%)

, GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

19:31
04/27/17
04/27
19:31
04/27/17
19:31
Hot Stocks
Google introduces development kit for Google Assistant »

Google announced in a…

GOOG

Alphabet

$874.25

2.52 (0.29%)

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:26
04/27/17
04/27
19:26
04/27/17
19:26
Hot Stocks
Sarepta: 'Productive' payer talks, ramping of patient starts continuing in Q2 »

"The number of exon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:22
04/27/17
04/27
19:22
04/27/17
19:22
Hot Stocks
Sarepta: Guidance includes only U.S. sales »

"Our guidance only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:20
04/27/17
04/27
19:20
04/27/17
19:20
Hot Stocks
Sarepta: Exondys post-market commitment data likely unavailable for couple years »

"The final protocols…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:18
04/27/17
04/27
19:18
04/27/17
19:18
Hot Stocks
Sarepta confirms CEO Ed Kaye to resign from role at end of current term »

Sarepta confirmed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BSAC

Santander Chile

$23.59

-0.36 (-1.50%)

19:02
04/27/17
04/27
19:02
04/27/17
19:02
Earnings
Santander Chile reports Q1 EPS 46c, consensus 42c »

Reports Q1 ROAE up 140…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

19:01
04/27/17
04/27
19:01
04/27/17
19:01
Hot Stocks
Canada gov't objects to Boeing allegations over Bombardier pricing in U.S. »

The Government of Canada…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

18:56
04/27/17
04/27
18:56
04/27/17
18:56
Periodicals
Boeing requests U.S. take action on Bombardier C series prices in U.S., FT says »

Boeing (BA) is aiming to…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SWN

Southwestern Energy

$7.67

-0.16 (-2.04%)

18:48
04/27/17
04/27
18:48
04/27/17
18:48
Earnings
Southwestern Energy reports Q1 adjusted EPS 18c, consensus 18c »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CRMD

CorMedix

$1.04

-0.07 (-6.31%)

18:43
04/27/17
04/27
18:43
04/27/17
18:43
Syndicate
CorMedix files to sell common stock warrants, no amount given »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:39
04/27/17
04/27
18:39
04/27/17
18:39
Earnings
Breaking Earnings news story on Forum Energy »

Forum Energy sees Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

WDC

Western Digital

$85.71

1.1 (1.30%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Hot Stocks
Western Digital: NAND supply-demand likely favorable through 'at least' 1H18 »

"Industry-wide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Earnings
Forum Energy reports Q1 adjusted EPS (14c), consensus (16c) »

Reports Q1 revenue $171M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SJR

Shaw Communications

$21.30

0.07 (0.33%)

18:36
04/27/17
04/27
18:36
04/27/17
18:36
Hot Stocks
Shaw Communications restores internet and phone services after brief outage »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Breaking Earnings news story on Matrix Service »

Matrix Service sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

$36.00

-0.6 (-1.64%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Gigamon sees Q2 adjusted EPS 2c-7c, consensus 19c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.